secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001193125-26-063974
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib
--------------------------------------------------------------------------------

- Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.
- Raised $264M from healthcare specialist funds in 2025 via private placement ($124.4M) and ATM ($117.6M).
- R&D expenses Q4 2025 $25.9M (down 19% YoY); full year 2025 $109.8M (down 4% YoY).
- Rinzimetostat Phase 1b: 55% PSA50, 20% PSA90, 76% ctDNA reduction; favorable safety vs competitors.
- Enozertinib Phase 1b: 67% ORR in 1L EGFR exon20, 80% ORR in 1L EGFR PACC; 100% intracranial ORR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/0001193125-26-063974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526063974/oric-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-063974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer